Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.

@article{Shiramizu2015ImpactOP,
  title={Impact of persistent minimal residual disease post-consolidation therapy in children and adolescents with advanced Burkitt leukaemia: a Children's Oncology Group Pilot Study Report.},
  author={Bruce Shiramizu and Stanton C. Goldman and Lynette M. Smith and Melissa A Agsalda-Garcia and Paul J Galardy and Sherrie L. Perkins and John Kimble Frazer and Warren G. Sanger and James R. Anderson and Thomas G. Gross and Howard J. Weinstein and Lauren A. Harrison and Matthew J. Barth and Lara Mussolin and Mitchell S Cairo},
  journal={British journal of haematology},
  year={2015},
  volume={170 3},
  pages={367-71}
}
Patient-specific primers from 10 children/adolescents with Burkitt leukaemia (BL) ± central nervous system disease who were treated with French-British-American/Lymphome Malins de Burkitt 96 C1 plus rituximab were developed from diagnostic blood/bone marrow. Minimal residual disease (MRD) was assessed by real-time polymerase chain reaction at the end of… CONTINUE READING